Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda
Authors:
- Philippa MusokePMPhilippa Musoke
- David L. HomDHDavid L. Hom
- Clemensia NakabiitoCNClemensia Nakabiito
- Danstan BagendaDBDanstan Bagenda
- Courtney V. FletcherCFCourtney V. Fletcher
- Lawrence H. MarumLMLawrence H. Marum
- Mary Glenn FowlerMFMary Glenn Fowler
- Lars G. FalksvedenLFLars G. Falksveden
- Britta WahrenBWBritta Wahren
- Peter KataahaPKPeter Kataaha
- Hans WigzellHWHans Wigzell
- 1 July 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (10) , 1391-1400
Abstract
To assess the safety, tolerance, pharmacokinetics, and virologic and immunologic changes associated with the use of Ugandan HIV hyperimmune globulin (HIVIGLOB) in HIV infected pregnant Ugandan women and their infants. A prospective, phase I/II, three-arm dose escalation trial of HIVIGLOB. HIVIGLOB was prepared from discarded HIV infected units of blood collected from the National Blood Bank in Kampala. From June 1996 to April 1997, 31 HIV positive pregnant women were enrolled with HIVIGLOB infusions given at 37 weeks gestation and within 16 h of birth for infants. The first 10 mother–infant pairs were infused at a dose of 50 mg/kg, followed by 11 pairs at 200 mg/kg, and 10 pairs at 400 mg/kg. Study participants were followed for 30 months. Thirty-one women and 29 infants were infused with HIVIGLOB. The infusions were safe and well tolerated by the women and their infants at all doses. There were no significant changes in virologic or immunologic parameters after HIVIGLOB infusion. Pharmacokinetic properties of this product were similar to other immune globulin products with a median half-life of 28 days in women and 30 days in infants. An HIV immune globulin product derived from HIV infected Ugandan donors is safe, well tolerated, and has pharmacokinetic properties consistent with other immunoglobulin products. Data suggest that a 400 mg/kg dose of HIVIGLOB would be the most appropriate dose for a subsequent efficacy trial of HIVIGLOB for the prevention of mother to child HIV transmission.Keywords
This publication has 41 references indexed in Scilit:
- Use of Human Immunodeficiency Virus (HIV) Human Hyperimmune Immunoglobulin in HIV Type 1–Infected Children (Pediatric AIDS Clinical Trials Group Protocol 273)The Journal of Infectious Diseases, 2000
- Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trialThe Lancet, 1999
- 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trialThe Lancet, 1999
- Safety and Pharmacokinetics of Hyperimmune Anti-Human Immunodeficiency Virus (HIV) Immunoglobulin Administered to HIV-Infected Pregnant Women and Their NewbornsThe Journal of Infectious Diseases, 1997
- Protection of neonatal kittens against feline immunodeficiency virus infection with passive maternal antiviral antibodiesAIDS, 1995
- Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeysNature, 1991
- Nucleotide Sequence of a Ugandan HIV-1 Provirus Reveals Genetic Diversity from Other HIV-1 IsolatesAIDS Research and Human Retroviruses, 1990
- Intravenous Gamma-Globulin In PregnancyObstetrical & Gynecological Survey, 1989
- PASSIVE IMMUNONEUTRALISATION OF HUMAN IMMUNODEFICIENCY VIRUS IN PATIENTS WITH ADVANCED AIDSThe Lancet, 1988
- SEROLOGICAL MARKERS IN EARLY STAGES OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HAEMOPHILIACSThe Lancet, 1986